Literature DB >> 25650288

Risk of second primary malignancies in women with breast cancer: Results from the European prospective investigation into cancer and nutrition (EPIC).

Fulvio Ricceri1,2, Francesca Fasanelli1, Maria Teresa Giraudo2, Sabina Sieri3, Rosario Tumino4, Amalia Mattiello5, Liliana Vagliano6, Giovanna Masala7, J Ramón Quirós8, Noemie Travier9, María-José Sánchez10,11, Nerea Larranaga12, María-Dolores Chirlaque11,13, Eva Ardanaz11,14, Anne Tjonneland15, Anja Olsen15, Kim Overvad16, Jenny Chang-Claude17, Rudolf Kaaks17, Heiner Boeing18, Françoise Clavel-Chapelon19,20,21, Marina Kvaskoff19,20,21, Laure Dossus19,20,21, Antonia Trichopoulou22,23, Vassiliki Benetou22, George Adarakis23, H B As Bueno-de-Mesquita24,25,26,27, Petra H Peeters28, Malin Sund29, Anne Andersson30, Signe Borgquist31, Salma Butt32, Elisabete Weiderpass33,34,35,36, Guri Skeie33, Kay-Tee Khaw37, Ruth C Travis38, Sabina Rinaldi39, Isabelle Romieu39, Marc Gunter40, Mai Kadi40, Elio Riboli40, Paolo Vineis40,41, Carlotta Sacerdote1.   

Abstract

Women with a diagnosis of breast cancer are at increased risk of second primary cancers, and the identification of risk factors for the latter may have clinical implications. We have followed-up for 11 years 10,045 women with invasive breast cancer from a European cohort, and identified 492 second primary cancers, including 140 contralateral breast cancers. Expected and observed cases and Standardized Incidence Ratios (SIR) were estimated using Aalen-Johansen Markovian methods. Information on various risk factors was obtained from detailed questionnaires and anthropometric measurements. Cox proportional hazards regression models were used to estimate the role of risk factors. Women with breast cancer had a 30% excess risk for second malignancies (95% confidence interval-CI 18-42) after excluding contralateral breast cancers. Risk was particularly elevated for colorectal cancer (SIR, 1.71, 95% CI 1.43-2.00), lymphoma (SIR 1.80, 95% CI 1.31-2.40), melanoma (2.12; 1.63-2.70), endometrium (2.18; 1.75-2.70) and kidney cancers (2.40; 1.57-3.52). Risk of second malignancies was positively associated with age at first cancer, body mass index and smoking status, while it was inversely associated with education, post-menopausal status and a history of full-term pregnancy. We describe in a large cohort of women with breast cancer a 30% excess of second primaries. Among risk factors for breast cancer, a history of full-term pregnancy was inversely associated with the risk of second primary cancer.
© 2015 UICC.

Entities:  

Keywords:  Aalen-Johansen estimator; breast cancer; second primary tumours; tumour size

Mesh:

Year:  2015        PMID: 25650288     DOI: 10.1002/ijc.29462

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution.

Authors:  Katie S Murray; Emily C Zabor; Massimiliano Spaliviero; Paul Russo; Wassim M Bazzi; John E Musser; A Ari Hakimi; Melanie L Bernstein; Guido Dalbagni; Jonathan A Coleman; Helena Furberg
Journal:  World J Urol       Date:  2016-04-22       Impact factor: 4.226

2.  Prediagnosis Body Mass Index and Risk of Secondary Primary Cancer in Male Cancer Survivors: A Large Cohort Study.

Authors:  Sang Min Park; Young Ho Yun; Young Ae Kim; Minkyung Jo; Young-Joo Won; Joung Hwan Back; Eun-Sook Lee
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

3.  Risk and Survival of Third Primary Cancers in a Population-Based Cohort of Breast Cancer Patients.

Authors:  Samantha Morais; Elisabete Gonçalves; Filipa Fontes; Jéssica Rodrigues; Rita Calisto; Maria José Bento; Nuno Lunet
Journal:  Breast Care (Basel)       Date:  2022-01-19       Impact factor: 2.268

4.  NCCN Guidelines Insights: Survivorship, Version 2.2020.

Authors:  Crystal S Denlinger; Tara Sanft; Javid J Moslehi; Linda Overholser; Saro Armenian; K Scott Baker; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Norah Lynn Henry; Christine Hill-Kayser; Melissa Hudson; Nazanin Khakpour; Divya Koura; Allison L McDonough; Michelle Melisko; Kathi Mooney; Halle C F Moore; Natalie Moryl; Tracey O'Connor; Electra D Paskett; Chirayu Patel; Lindsay Peterson; William Pirl; M Alma Rodriguez; Kathryn J Ruddy; Lillie Shockney; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2020-08       Impact factor: 11.908

5.  Correlates of objectively measured sedentary behavior in breast cancer survivors.

Authors:  Siobhan M Phillips; Gillian R Lloyd; Elizabeth A Awick; Edward McAuley
Journal:  Cancer Causes Control       Date:  2016-05-04       Impact factor: 2.506

6.  Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls.

Authors:  Kathy Pan; Rowan T Chlebowski; Michael S Simon; Roberta M Ray; Jennifer Livaudais-Toman; Shannon D Sullivan; Marcia L Stefanick; Robert B Wallace; Meryl LeBoff; Elizabeth Carhart Bluhm; Electra D Paskett
Journal:  Breast Cancer Res Treat       Date:  2016-04-13       Impact factor: 4.872

7.  Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study.

Authors:  Julia S Sisti; Jonine L Bernstein; Charles F Lynch; Anne S Reiner; Lene Mellemkjaer; Jennifer D Brooks; Julia A Knight; Leslie Bernstein; Kathleen E Malone; Meghan Woods; Xiaolin Liang; Esther M John
Journal:  Springerplus       Date:  2015-12-30

8.  Germline large genomic alterations on 7q in patients with multiple primary cancers.

Authors:  R A R Villacis; T R Basso; L M Canto; A F Nóbrega; M I Achatz; S R Rogatto
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379

9.  Breast Cancer (BC) Is a Window of Opportunity for Smoking Cessation: Results of a Retrospective Analysis of 1234 BC Survivors in Follow-Up Consultation.

Authors:  Marion Nicolas; Beatriz Grandal; Emma Dubost; Amyn Kassara; Julien Guerin; Aullene Toussaint; Enora Laas; Jean-Guillaume Feron; Virginie Fourchotte; Fabrice Lecuru; Noemie Girard; Florence Coussy; Beatrice Lavielle; Irene Kriegel; Youlia Kirova; Jean-Yves Pierga; Fabien Reyal; Anne-Sophie Hamy
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

10.  Inhibition of estrogen biosynthesis enhances lymphoma growth in mice.

Authors:  Gergely Talaber; Konstantin Yakimchuk; Jiyu Guan; Jose Inzunza; Sam Okret
Journal:  Oncotarget       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.